Recombinant human erythropoietin improves neurological outcomes in very preterm infants

Juan Song, Huiqing Sun, Falin Xu, Wenqing Kang, Liang Gao, Jiajia Guo, Yanhua Zhang, Lei Xia, Xiaoyang Wang, Changlian Zhu, Juan Song, Huiqing Sun, Falin Xu, Wenqing Kang, Liang Gao, Jiajia Guo, Yanhua Zhang, Lei Xia, Xiaoyang Wang, Changlian Zhu

Abstract

Objective: To evaluate the efficacy and safety of repeated low-dose human recombinant erythropoietin (rhEPO) in the improvement of neurological outcomes in very preterm infants.

Methods: A total of 800 infants of ≤32-week gestational age who had been in an intensive care unit within 72 hours after birth were included in the trial between January 2009 and June 2013. Preterm infants were randomly assigned to receive rhEPO (500IU/kg; n = 366) or placebo (n = 377) intravenously within 72 hours after birth and then once every other day for 2 weeks. The primary outcome was death or moderate to severe neurological disability assessed at 18 months of corrected age.

Results: Death and moderate/severe neurological disability occurred in 91 of 338 very preterm infants (26.9%) in the placebo group and in 43 of 330 very preterm infants (13.0%) in the rhEPO treatment group (relative risk [RR] = 0.40, 95% confidence interval [CI] = 0.27-0.59, p < 0.001) at 18 months of corrected age. The rate of moderate/severe neurological disability in the rhEPO group (22 of 309, 7.1%) was significantly lower compared to the placebo group (57 of 304, 18.8%; RR = 0.32, 95% CI = 0.19-0.55, p < 0.001), and no excess adverse events were observed.

Interpretation: Repeated low-dose rhEPO treatment reduced the risk of long-term neurological disability in very preterm infants with no obvious adverse effects. Ann Neurol 2016;80:24-34.

© 2016 The Authors. Annals of Neurology published by Wiley Periodicals, Inc. on behalf of American Neurological Association.

Figures

Figure 1
Figure 1
Study flow. Schematic flowchart shows the numbers of infants who were screened for eligibility, randomly assigned to recombinant human erythropoietin (rhEPO) or placebo groups, and followed up to 18 months of corrected age. Lost to follow‐up means that contact with the family was lost during the follow‐up period. ICH = intracranial hemorrhage; NEC = necrotizing enterocolitis.

References

    1. Kinney MV, Lawn JE, Howson CP, Belizan J. 15 Million preterm births annually: what has changed this year? Reprod Health 2012;9:28.
    1. Liu L, Johnson HL, Cousens S, et al. Global, regional, and national causes of child mortality: an updated systematic analysis for 2010 with time trends since 2000. Lancet 2012;379:2151–2161.
    1. Serenius F, Kallen K, Blennow M, et al. Neurodevelopmental outcome in extremely preterm infants at 2.5 years after active perinatal care in Sweden. JAMA 2013;309:1810–1820.
    1. Hintz SR, Kendrick DE, Wilson‐Costello DE, et al. Early‐childhood neurodevelopmental outcomes are not improving for infants born at <25 weeks' gestational age. Pediatrics 2011;127:62–70.
    1. Juul SE, Ferriero DM. Pharmacologic neuroprotective strategies in neonatal brain injury. Clin Perinatol 2014;41:119–131.
    1. Maier RF, Obladen M, Muller‐Hansen I, et al. Early treatment with erythropoietin beta ameliorates anemia and reduces transfusion requirements in infants with birth weights below 1000 g. J Pediatr 2002;141:8–15.
    1. Sargin D, El‐Kordi A, Agarwal A, et al. Expression of constitutively active erythropoietin receptor in pyramidal neurons of cortex and hippocampus boosts higher cognitive functions in mice. BMC Biol 2011;9:27.
    1. Zhu C, Kang W, Xu F, et al. Erythropoietin improved neurologic outcomes in newborns with hypoxic‐ischemic encephalopathy. Pediatrics 2009;124:e218–e226.
    1. Traudt CM, McPherson RJ, Bauer LA, et al. Concurrent erythropoietin and hypothermia treatment improve outcomes in a term nonhuman primate model of perinatal asphyxia. Dev Neurosci 2013;35:491–503.
    1. Hellstrom‐Westas L, Rosen I. Continuous brain‐function monitoring: state of the art in clinical practice. Semin Fetal Neonatal Med 2006;11:503–511.
    1. Siren AL, Knerlich F, Poser W, et al. Erythropoietin and erythropoietin receptor in human ischemic/hypoxic brain. Acta Neuropathol 2001;101:271–276.
    1. Wang X, Zhu C, Wang X, et al. The nonerythropoietic asialoerythropoietin protects against neonatal hypoxia‐ischemia as potently as erythropoietin. J Neurochem 2004;91:900–910.
    1. Leist M, Ghezzi P, Grasso G, et al. Derivatives of erythropoietin that are tissue protective but not erythropoietic. Science 2004;305:239–242.
    1. Wu YW, Bauer LA, Ballard RA, et al. Erythropoietin for neuroprotection in neonatal encephalopathy: safety and pharmacokinetics. Pediatrics 2012;130:683–691.
    1. Elmahdy H, El‐Mashad AR, El‐Bahrawy H, et al. Human recombinant erythropoietin in asphyxia neonatorum: pilot trial. Pediatrics 2010;125:e1135–e1142.
    1. Leuchter RH, Gui L, Poncet A, et al. Association between early administration of high‐dose erythropoietin in preterm infants and brain MRI abnormality at term‐equivalent age. JAMA 2014;312:817–824.
    1. Neubauer AP, Voss W, Wachtendorf M, Jungmann T. Erythropoietin improves neurodevelopmental outcome of extremely preterm infants. Ann Neurol 2010;67:657–666.
    1. Rosebraugh MR, Widness JA, Nalbant D, et al. Pharmacodynamically optimized erythropoietin treatment combined with phlebotomy reduction predicted to eliminate blood transfusions in selected preterm infants. Pediatr Res 2014;75:336–342.
    1. Aher SM, Ohlsson A. Early versus late erythropoietin for preventing red blood cell transfusion in preterm and/or low birth weight infants. Cochrane Database Syst Rev 2012;10:CD004865.
    1. Juul SE, McPherson RJ, Bauer LA, et al. A phase I/II trial of high‐dose erythropoietin in extremely low birth weight infants: pharmacokinetics and safety. Pediatrics 2008;122:383–391.
    1. Bierer R, Peceny MC, Hartenberger CH, Ohls RK. Erythropoietin concentrations and neurodevelopmental outcome in preterm infants. Pediatrics 2006;118:e635–e640.
    1. Kandasamy Y, Kumar P, Hartley L. The effect of erythropoietin on the severity of retinopathy of prematurity. Eye 2014;28:814–818.
    1. Ohlsson A, Aher SM. Early erythropoietin for preventing red blood cell transfusion in preterm and/or low birth weight infants. Cochrane Database Syst Rev 2014;4:CD004863.
    1. Ballot DE, Potterton J, Chirwa T, et al. Developmental outcome of very low birth weight infants in a developing country. BMC Pediatr 2012;12:11.
    1. Vazquez Lopez MA, Llamas MA, Galera R, et al. Comparison between one and three doses a week of recombinant erythropoietin in very low birth weight infants. J Perinatol 2011;31:118–124.
    1. Song J, Xu F, Wang L, et al. Early amplitude‐integrated electroencephalography predicts brain injury and neurological outcome in very preterm infants. Sci Rep 2015;5:13810.
    1. Papile LA, Burstein J, Burstein R, Koffler H. Incidence and evolution of subependymal and intraventricular hemorrhage: a study of infants with birth weights less than 1,500 gm. J Pediatr 1978;92:529–534.
    1. de Vries LS, Eken P, Dubowitz LM. The spectrum of leukomalacia using cranial ultrasound. Behav Brain Res 1992;49:1–6.
    1. Smyser CD, Snyder AZ, Shimony JS, et al. Effects of white matter injury on resting state fMRI measures in prematurely born infants. PLoS One 2013;8:e68098.
    1. Ehrenkranz RA, Walsh MC, Vohr BR, et al. Validation of the National Institutes of Health consensus definition of bronchopulmonary dysplasia. Pediatrics 2005;116:1353–1360.
    1. Berman L, Moss RL. Necrotizing enterocolitis: an update. Semin Fetal Neonatal Med 2011;16:145–150.
    1. Yu XD, Branch DW, Karumanchi SA, Zhang J. Preeclampsia and retinopathy of prematurity in preterm births. Pediatrics 2012;130:e101–e107.
    1. McAdams RM, McPherson RJ, Mayock DE, Juul SE. Outcomes of extremely low birth weight infants given early high‐dose erythropoietin. J Perinatol 2013;33:226–230.
    1. Fan X, Heijnen CJ, van der KM, et al. Beneficial effect of erythropoietin on sensorimotor function and white matter after hypoxia‐ischemia in neonatal mice. Pediatr Res 2011;69:56–61.
    1. Liu W, Shen Y, Plane JM, et al. Neuroprotective potential of erythropoietin and its derivative carbamylated erythropoietin in periventricular leukomalacia. Exp Neurol 2011;230:227–239.
    1. O'Gorman RL, Bucher HU, Held U, et al. Tract‐based spatial statistics to assess the neuroprotective effect of early erythropoietin on white matter development in preterm infants. Brain 2015;138(pt 2):388–397.
    1. Fauchere JC, Dame C, Vonthein R, et al. An approach to using recombinant erythropoietin for neuroprotection in very preterm infants. Pediatrics 2008;122:375–382.
    1. Ohls RK, Kamath‐Rayne BD, Christensen RD, et al. Cognitive outcomes of preterm infants randomized to darbepoetin, erythropoietin, or placebo. Pediatrics 2014;133:1023–1030.
    1. Larroque B, Ancel PY, Marret S, et al. Neurodevelopmental disabilities and special care of 5‐year‐old children born before 33 weeks of gestation (the EPIPAGE study): a longitudinal cohort study. Lancet 2008;371:813–820.
    1. Xia L, Sun L, Wang X, et al. Changes in the incidence of congenital anomalies in Henan Province, China, from 1997 to 2011. PLoS One 2015;10:e0131874.
    1. Peacock JL, Marston L, Marlow N, et al. Neonatal and infant outcome in boys and girls born very prematurely. Pediatr Res 2012;71:305–310.
    1. Fauchere JC, Koller BM, Tschopp A, et al. Safety of early high‐dose recombinant erythropoietin for neuroprotection in very preterm infants. J Pediatr 2015;167:52–57.
    1. Marlow N, Morris T, Brocklehurst P, et al. A randomised trial of granulocyte‐macrophage colony‐stimulating factor for neonatal sepsis: childhood outcomes at 5 years. Arch Dis Child Fetal Neonatal Ed 2015;100:F320–F326.
    1. Ohls RK, Roohi M, Peceny HM, et al. A randomized, masked study of weekly erythropoietin dosing in preterm infants. J Pediatr 2012;160:790–795.
    1. Kellert BA, McPherson RJ, Juul SE. A comparison of high‐dose recombinant erythropoietin treatment regimens in brain‐injured neonatal rats. Pediatr Res 2007;61:451–455.
    1. Brown MS, Eichorst D, Lala‐Black B, Gonzalez R. Higher cumulative doses of erythropoietin and developmental outcomes in preterm infants. Pediatrics 2009;124:e681–e687.
    1. Watanabe D, Suzuma K, Matsui S, et al. Erythropoietin as a retinal angiogenic factor in proliferative diabetic retinopathy. N Engl J Med 2005;353:782–792.
    1. Schneider JK, Gardner DK, Cordero L. Use of recombinant human erythropoietin and risk of severe retinopathy in extremely low‐birth‐weight infants. Pharmacotherapy 2008;28:1335–1340.
    1. Shiou SR, Yu Y, Chen S, et al. Erythropoietin protects intestinal epithelial barrier function and lowers the incidence of experimental neonatal necrotizing enterocolitis. J Biol Chem 2011;286:12123–12132.
    1. Vollmar B, Eipel C, Menger MD. Therapeutic effects of erythropoietin in murine models of endotoxin shock. Crit Care Med 2010;38:340–341.

Source: PubMed

스폰서 및 공동 작업자

건강 상태

약물 개입

3
구독하다